- Home
- VACH vs RIGL Comparison
VACH vs RIGL Comparison
Compare VACH & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VACH
- RIGL
- Stock Information
- Founded
- VACH 2023
- RIGL 1996
- Country
- VACH United States
- RIGL United States
- Employees
- VACH N/A
- RIGL N/A
- Industry
- VACH
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- VACH
- RIGL Health Care
- Exchange
- VACH NYSE
- RIGL Nasdaq
- Market Cap
- VACH 274.7M
- RIGL 247.1M
- IPO Year
- VACH 2024
- RIGL 2000
- Fundamental
- Price
- VACH $10.03
- RIGL $24.10
- Analyst Decision
- VACH
- RIGL Buy
- Analyst Count
- VACH 0
- RIGL 5
- Target Price
- VACH N/A
- RIGL $31.30
- AVG Volume (30 Days)
- VACH 7.9K
- RIGL 276.8K
- Earning Date
- VACH 01-01-0001
- RIGL 11-07-2024
- Dividend Yield
- VACH N/A
- RIGL N/A
- EPS Growth
- VACH N/A
- RIGL N/A
- EPS
- VACH N/A
- RIGL 0.22
- Revenue
- VACH N/A
- RIGL $157,374,000.00
- Revenue This Year
- VACH N/A
- RIGL $38.26
- Revenue Next Year
- VACH N/A
- RIGL $24.21
- P/E Ratio
- VACH N/A
- RIGL $108.84
- Revenue Growth
- VACH N/A
- RIGL 21.65
- 52 Week Low
- VACH $9.97
- RIGL $7.48
- 52 Week High
- VACH $10.10
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- VACH N/A
- RIGL 69.60
- Support Level
- VACH N/A
- RIGL $13.91
- Resistance Level
- VACH N/A
- RIGL $29.16
- Average True Range (ATR)
- VACH 0.00
- RIGL 1.98
- MACD
- VACH 0.00
- RIGL 1.23
- Stochastic Oscillator
- VACH 0.00
- RIGL 64.80
About VACH VOYAGER ACQUISITION CORP.
Voyager Acquisition Corp is a blank check company.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.